132
Participants
Start Date
October 23, 2006
Primary Completion Date
July 9, 2025
Study Completion Date
July 9, 2026
Eribulin Mesylate
Given IV
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Northern Indiana Cancer Research Consortium, South Bend
Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne
Community Howard Regional Health, Kokomo
University of Michigan Comprehensive Cancer Center, Ann Arbor
Wayne State University/Karmanos Cancer Institute, Detroit
Oncology Care Associates PLLC, Saint Joseph
Medical College of Wisconsin, Milwaukee
Loyola University Medical Center, Maywood
NorthShore University HealthSystem-Evanston Hospital, Evanston
Ingalls Memorial Hospital, Harvey
Duly Health and Care Joliet, Joliet
University of Chicago Comprehensive Cancer Center, Chicago
Illinois CancerCare-Peoria, Peoria
Decatur Memorial Hospital, Decatur
Central Illinois Hematology Oncology Center, Springfield
Southern Illinois University School of Medicine, Springfield
Mercy Hospital Saint Louis, St Louis
USC / Norris Comprehensive Cancer Center, Los Angeles
Tower Cancer Research Foundation, Beverly Hills
City of Hope Comprehensive Cancer Center, Duarte
City of Hope South Pasadena, South Pasadena
City of Hope Antelope Valley, Lancaster
Veterans Administration Hospital - Martinez, Martinez
University of California Davis Comprehensive Cancer Center, Sacramento
Contra Costa Regional Medical Center, Martinez
National Cancer Institute (NCI)
NIH